A real-world investigation of drug-induced hyperglycemia and diabetes mellitus in pediatric populations using the FDA adverse event reporting system

Key Points

• Drug-induced hyperglycemia was systematically analyzed, revealing significant risk signals in pediatric populations.
• The investigation identified age-related susceptibility windows for children exposed to diabetogenic agents.
• Assessment using the FDA adverse event reporting system helps reveal critical patterns in drug safety for children.
• The findings suggest clinicians should increase surveillance for diabetes when prescribing certain medications to younger patients.